RxDoctor Payments Data

Joshua Yager, MD

Family Medicine · Chamblee, GANPI 1134515448

Payments from drug & device makers

$2,356in general payments, 2019–2025

Across 115 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$563
  • Gilead$526
  • Novo Nordisk$281
  • Lilly USA, LLC$142
  • Braeburn Inc.$139
  • Takeda Pharmaceuticals U.S.A., Inc.$124
  • plus $583 from 14 others

What the payments were for

  • Food & beverage$2,356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,356 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$61,149
Medicare patients
155
Services billed
2,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide21$40,652
OzempicSemaglutide29$40,024
XareltoRivaroxaban23$23,678
EliquisApixaban14$12,317
Repatha SyringeEvolocumab12$6,763
Atorvastatin Calcium188$1,692
SynthroidLevothyroxine Sodium11$1,456
Amlodipine-ValsartanAmlodipine Besylate/Valsartan11$1,451
Pantoprazole Sodium71$1,254
Finasteride47$842
Tamsulosin Hcl37$808
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$803
Metoprolol Succinate46$774
Losartan Potassium72$733
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide40$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$281$80,67650 claims
PfizerEliquis$50$12,31714 claims
AbbVieSynthroid$14$1,45611 claims
Almatica Pharma LLCSertraline Hcl$38$48228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Chamblee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →